NeuroSense Therapeutics Ltd. (NRSN) stock
Close on Nov 13, 2026Market cap $3.10MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $3.10M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -247.46%
Fundamentals
- Net income
- -$11.13M
- EPS, diluted
- -$8.80
- Free cash flow
- -$7.68M
Trading
- Previous close
- $1.76
- Open
- $1.72
- Day's range
- $1.59 – $1.78
- Volume
- 18,305
- Average volume (20 days)
- 49,778
- Beta (5 years)
- 1.30
- 52-week range
- $1.10 – $25.40
- RSI (14 days)
- 31.4
- Volatility (1 year)
- 101.0%
- Relative volume
- 0.67×
- WACC
- 11.6%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | NRSN | S&P 500 | Difference | NRSN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -51.6% | -3.0% | −48.5 pts | ||
| 3 months | -80.9% | -2.8% | −78.1 pts | ||
| Year to date | -89.0% | +11.5% | −100.5 pts | ||
| 1 year | -90.8% | +13.5% | −104.3 pts | ||
| 3 years | -83.1% | +77.7% | −160.8 pts | -44.7% | +21.1% |
Eight years at a glance
Fiscal years 2018 to 2025, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases NeuroSense Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About NeuroSense Therapeutics
Pharmaceutical Preparations
NeuroSense Therapeutics Ltd. is a clinical-stage biopharmaceutical company focused on the research and development of treatments for neurodegenerative diseases. Its lead product candidate is PrimeC, a novel therapeutic designed to treat Amyotrophic Lateral Sclerosis (ALS). In addition to PrimeC, the company maintains research programs exploring preclinical product candidates for other neurodegenerative conditions. As a development-stage entity without approved commercial products, NeuroSense does not yet serve commercial customers or patients directly, with its operational activities centering on preclinical studies and clinical trials.
Company profile, executives and historyNeuroSense Therapeutics stock: common questions
What is NeuroSense Therapeutics's stock price?
NRSN closed at $1.69 on Nov 13, 2026, down 3.98% on the day. Over the past 52 weeks it traded between $1.10 and $25.40.
What is NeuroSense Therapeutics's market cap?
NeuroSense Therapeutics was worth $3.10M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is NRSN's P/E ratio?
NeuroSense Therapeutics lost money over fiscal 2025 (diluted EPS -$8.80), so it has no meaningful P/E ratio.
Does NeuroSense Therapeutics pay a dividend?
No. NeuroSense Therapeutics has not paid a cash dividend over the last twelve months.
How has NRSN stock performed over the past year?
Including dividends, NRSN returned -90.8% over the past year, against +13.5% for the S&P 500.
Who are NeuroSense Therapeutics's competitors?
Companies most similar to NeuroSense Therapeutics by business, industry and size include SPRB, SPRC, AMLX, COYA, MNOV.
See a number that looks wrong?